Renal Cell Neoplasia Tables: Recurrent Cytogenomic Alterations - Revision history

Kilannin.Krysiak: Minor tidying of references

2021-05-19T18:40:19Z

Minor tidying of references

← Older revision		Revision as of 13:40, 19 May 2021
Line 329:		Line 329:
	\|-		\|-
	\|'''References'''		\|'''References'''
	~~\|[9<ref~~		\|<ref name=
	\|}		\|}
	Note: <sup>a</sup> level of evidence (ranges from level 1 to 3 as specified in the methods). Level 1, established clinical significance and present in current WHO classification and/or professional practice guidelines such as NCCN, ASCO, CAP guidelines or FDA approval; Level 2, recurrent clinical significance based on large studies with outcomes; and Level 3, recurrent but uncertain clinical significance based on smaller studies and multiple case reports.		Note: <sup>a</sup> level of evidence (ranges from level 1 to 3 as specified in the methods). Level 1, established clinical significance and present in current WHO classification and/or professional practice guidelines such as NCCN, ASCO, CAP guidelines or FDA approval; Level 2, recurrent clinical significance based on large studies with outcomes; and Level 3, recurrent but uncertain clinical significance based on smaller studies and multiple case reports.

Jennelleh: Jennelleh moved page RenalTable to Renal Cell Neoplasia Tables: Recurrent Cytogenomic Alterations without leaving a redirect

2021-04-22T22:49:31Z

Jennelleh moved page RenalTable to Renal Cell Neoplasia Tables: Recurrent Cytogenomic Alterations without leaving a redirect

← Older revision		Revision as of 17:49, 22 April 2021
(No difference)

Jennelleh at 22:48, 22 April 2021

2021-04-22T22:48:51Z

← Older revision		Revision as of 17:48, 22 April 2021
Line 1:		Line 1:
	{{DISPLAYTITLE:Renal Table: Recurrent Genomic Alterations Detected by Chromosomal Microarray}}		{{DISPLAYTITLE:Renal Table: Recurrent Genomic Alterations Detected by Chromosomal Microarray}}

	'''Table 1 - Recurrent Genomic Alterations in Renal Cell ~~Neoplasias~~ Detected by Chromosomal Microarray (Literature Review)'''. Genetic alterations and their associated clinical significance in major types of renal cell neoplasia. Table derived from Liu et al., 2020 [PMID 32434132] with permission from Cancer Genetics.		'''Table 1 - Recurrent Genomic Alterations in Renal Cell Neoplasia Detected by Chromosomal Microarray (Literature Review)'''. Genetic alterations and their associated clinical significance in major types of renal cell neoplasia. Table derived from Liu et al., 2020 [PMID 32434132] with permission from Cancer Genetics.
	{\| class="wikitable"		{\| class="wikitable"
	\| colspan="8" \|'''WHO Classification'''		\| colspan="8" \|'''WHO Classification'''
Line 23:		Line 23:
	\|15-20%		\|15-20%
	\|15-20%		\|15-20%
	\| colspan="2" \| 1-5%		\| colspan="2" \|1-5%
	\| 5%		\|5%
	\| 5%		\|5%
	\|-		\|-
	\|'''Origin'''		\|'''Origin'''
Line 44:		Line 44:
	\|1p- (10%) [2; R]		\|1p- (10%) [2; R]
	\|		\|
	\| 1p- (25%) [2; R]		\|1p- (25%) [2; R]
	\| colspan="2" \|1p- (30%) [3; R]		\| colspan="2" \|1p- (30%) [3; R]
	\|'''-1''' (90%) '''[1; D]<sup>c</sup>'''		\|'''-1''' (90%) '''[1; D]<sup>c</sup>'''
Line 263:		Line 263:
	\| colspan="8" \|'''Mutations (SNVs, Indels) [level of evidence; clinical significance]'''		\| colspan="8" \|'''Mutations (SNVs, Indels) [level of evidence; clinical significance]'''
	\|-		\|-
	\| Mutated		\|Mutated

	in >20%		in >20%
Line 273:		Line 273:
	\|		\|
	\|-		\|-
	\| Mutated		\|Mutated

	in 10-20%		in 10-20%
Line 315:		Line 315:
	\|Germline susceptibility		\|Germline susceptibility
	\|		\|
	* mainly ''[[VHL]]'' (von Hippel-Lindau Syndrome)		*mainly ''[[VHL]]'' (von Hippel-Lindau Syndrome)
	* ''[[PTEN]]'' (Cowden Syndrome)		*''[[PTEN]]'' (Cowden Syndrome)
	* ''[[FLCN]]'' (Birt-Hogg-Dube syndrome)		*''[[FLCN]]'' (Birt-Hogg-Dube syndrome)
	* ''[[TSC1]]'' and ''[[TSC2]]'' (tuberous sclerosis)		*''[[TSC1]]'' and ''[[TSC2]]'' (tuberous sclerosis)
	* ''[[SDHB]] (most common), [[SDHC]] (less common), [[SDHA]] (rare), [[SDHD]] (rare)'' (succinate dehydrogenase deficient RCC)		*''[[SDHB]] (most common), [[SDHC]] (less common), [[SDHA]] (rare), [[SDHD]] (rare)'' (succinate dehydrogenase deficient RCC)
	\|		\|
	* ''[[MET]]'' (Hereditary papillary RCC)		*''[[MET]]'' (Hereditary papillary RCC)
	\|		\|
	* ''[[FH]]'' (Hereditary leiomyomatosis and RCC)		*''[[FH]]'' (Hereditary leiomyomatosis and RCC)
	\|		\|
	\| colspan="2" \|''[[FCLN]]'' (Birt-Hogg-Dube syndrome)		\| colspan="2" \|''[[FCLN]]'' (Birt-Hogg-Dube syndrome)

Kilannin.Krysiak at 05:02, 15 January 2021

2021-01-15T05:02:15Z

← Older revision		Revision as of 00:02, 15 January 2021
Line 185:		Line 185:
	\|'''chr17'''		\|'''chr17'''
	\|		\|
	\|'''+17''' (84%) '''[1; D] <sup>c</sup>'''		\|'''+17''' (84%) '''[1; D]<sup>c</sup>'''
	\|17p- (8%) [3; R],		\|17p- (8%) [3; R],

Kilannin.Krysiak: added bullets

2021-01-15T05:01:25Z

added bullets

← Older revision		Revision as of 00:01, 15 January 2021
Line 314:		Line 314:
	\|-		\|-
	\|Germline susceptibility		\|Germline susceptibility
	\|§ mainly ''[[VHL]]'' (von Hippel-Lindau Syndrome)		\|
			* mainly ''[[VHL]]'' (von Hippel-Lindau Syndrome)
	§ ''[[PTEN]]'' (Cowden Syndrome)		* ''[[PTEN]]'' (Cowden Syndrome)
			* ''[[FLCN]]'' (Birt-Hogg-Dube syndrome)
	§ ''[[FLCN]]'' (Birt-Hogg-Dube syndrome)		* ''[[TSC1]]'' and ''[[TSC2]]'' (tuberous sclerosis)
			* ''[[SDHB]] (most common), [[SDHC]] (less common), [[SDHA]] (rare), [[SDHD]] (rare)'' (succinate dehydrogenase deficient RCC)
	§ ''[[TSC1]]'' and ''[[TSC2]]'' (tuberous sclerosis)		\|
			* ''[[MET]]'' (Hereditary papillary RCC)
	§ ''[[SDHB]] (most common), [[SDHC]] (less common), [[SDHA]] (rare), [[SDHD]] (rare)'' (succinate dehydrogenase deficient RCC)		\|
	\|§ ''[[MET]]'' (Hereditary papillary RCC)		* ''[[FH]]'' (Hereditary leiomyomatosis and RCC)
	\|§ ''[[FH]]'' (Hereditary leiomyomatosis and RCC)
	\|		\|
	\| colspan="2" \|''[[FCLN]]'' (Birt-Hogg-Dube syndrome)		\| colspan="2" \|''[[FCLN]]'' (Birt-Hogg-Dube syndrome)

Kilannin.Krysiak: legend change

2021-01-15T04:56:55Z

legend change

← Older revision		Revision as of 23:56, 14 January 2021
Line 1:		Line 1:
	{{DISPLAYTITLE:Renal Table: Recurrent Genomic Alterations Detected by Chromosomal Microarray}}		{{DISPLAYTITLE:Renal Table: Recurrent Genomic Alterations Detected by Chromosomal Microarray}}

	'''Table 1 - Recurrent Genomic Alterations in ~~AML~~ Detected by Chromosomal Microarray (Literature Review)'''. ~~This is a comprehensive list of CNAs~~ and ~~CN-LOH detectable by CMA testing with strong~~ clinical significance in major types of renal cell neoplasia. Table derived from Liu et al., 2020 [PMID 32434132] with permission from Cancer Genetics.		'''Table 1 - Recurrent Genomic Alterations in Renal Cell Neoplasias Detected by Chromosomal Microarray (Literature Review)'''. Genetic alterations and their associated clinical significance in major types of renal cell neoplasia. Table derived from Liu et al., 2020 [PMID 32434132] with permission from Cancer Genetics.
	{\| class="wikitable"		{\| class="wikitable"
	\| colspan="8" \|'''WHO Classification'''		\| colspan="8" \|'''WHO Classification'''

Kilannin.Krysiak: updating cgc reference

2021-01-15T04:53:46Z

updating cgc reference

← Older revision		Revision as of 23:53, 14 January 2021
Line 1:		Line 1:
	{{DISPLAYTITLE:Renal Table: Recurrent Genomic Alterations Detected by Chromosomal Microarray}}		{{DISPLAYTITLE:Renal Table: Recurrent Genomic Alterations Detected by Chromosomal Microarray}}

	'''Table 1 - Recurrent Genomic Alterations in AML Detected by Chromosomal Microarray (Literature Review)'''. This is a comprehensive list of CNAs and CN-LOH detectable by CMA testing with strong clinical significance in major types of renal cell neoplasia. Table derived from Liu et al., 2020 [PMID: 32434132] with permission from Cancer Genetics.		'''Table 1 - Recurrent Genomic Alterations in AML Detected by Chromosomal Microarray (Literature Review)'''. This is a comprehensive list of CNAs and CN-LOH detectable by CMA testing with strong clinical significance in major types of renal cell neoplasia. Table derived from Liu et al., 2020 [PMID 32434132] with permission from Cancer Genetics.
	{\| class="wikitable"		{\| class="wikitable"
	\| colspan="8" \|'''WHO Classification'''		\| colspan="8" \|'''WHO Classification'''
Line 344:		Line 344:
	==Reference==		==Reference==

	1. ~~Xu X~~, ~~Bryke C~~, ~~Sukhanova M, Huxley E, Dash DP, Dixon-Mciver A, Fang M, Griepp PT, Hodge JC, Iqbal A, Jeffries S, Kanagal-Shamanna~~ R, ~~Quintero-Rivera F~~, ~~Shetty S, Slovak ML, Yenamandra A, Lennon PA, Raca G. (2018)~~. Assessing ~~copy number abnormalities and copy-neutral loss-of-heterozygosity across the genome~~ as ~~best practice in diagnostic evaluation of acute myeloid leukemia~~: An ~~evidence~~-~~based review~~ from the ~~cancer genomics consortium (CGC) myeloid neoplasms working group~~. Cancer Genet [Epub ~~ahead of print],~~ PMID ~~30344013~~.		1. Liu YJ, Houldsworth J, Emmadi R, Dyer L, Wolff DJ. Assessing Genomic Copy Number Alterations as Best Practice for Renal Cell Neoplasia: An Evidence-Based Review from the Cancer Genomics Consortium Workgroup. Cancer Genet. 2020 Jun;244:40-54. doi: 10.1016/j.cancergen.2020.04.004. Epub 2020 May 1. PMID 32434132.
	<references />		<references />

Kilannin.Krysiak at 04:49, 15 January 2021

2021-01-15T04:49:34Z

← Older revision		Revision as of 23:49, 14 January 2021
Line 341:		Line 341:

	<sup>c</sup> alterations in combination		<sup>c</sup> alterations in combination

			==Reference==

			1. Xu X, Bryke C, Sukhanova M, Huxley E, Dash DP, Dixon-Mciver A, Fang M, Griepp PT, Hodge JC, Iqbal A, Jeffries S, Kanagal-Shamanna R, Quintero-Rivera F, Shetty S, Slovak ML, Yenamandra A, Lennon PA, Raca G. (2018). Assessing copy number abnormalities and copy-neutral loss-of-heterozygosity across the genome as best practice in diagnostic evaluation of acute myeloid leukemia: An evidence-based review from the cancer genomics consortium (CGC) myeloid neoplasms working group. Cancer Genet [Epub ahead of print], PMID 30344013.
			<references />

Kilannin.Krysiak: finishing references

2021-01-15T04:48:02Z

finishing references

← Older revision		Revision as of 23:48, 14 January 2021
Line 330:		Line 330:
	\|-		\|-
	\|'''References'''		\|'''References'''
	~~\|[9<ref~~		\|[9<ref
	\|}		\|}
	Note: <sup>a</sup> level of evidence (ranges from level 1 to 3 as specified in the methods). Level 1, established clinical significance and present in current WHO classification and/or professional practice guidelines such as NCCN, ASCO, CAP guidelines or FDA approval; Level 2, recurrent clinical significance based on large studies with outcomes; and Level 3, recurrent but uncertain clinical significance based on smaller studies and multiple case reports.		Note: <sup>a</sup> level of evidence (ranges from level 1 to 3 as specified in the methods). Level 1, established clinical significance and present in current WHO classification and/or professional practice guidelines such as NCCN, ASCO, CAP guidelines or FDA approval; Level 2, recurrent clinical significance based on large studies with outcomes; and Level 3, recurrent but uncertain clinical significance based on smaller studies and multiple case reports.

Kilannin.Krysiak: adding some of the citations (saving interim to not lose work)

2021-01-15T04:26:11Z

adding some of the citations (saving interim to not lose work)

Show changes